HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dexmedetomidine combined with sufentanil and dezocine-based patient-controlled intravenous analgesia increases female patients' global satisfaction degree after thoracoscopic surgery.

AbstractBACKGROUND:
There are no studies on the use of dexmedetomidine combined with sufentanil and dezocine-based patient-controlled intravenous analgesia (PCIA) in females undergoing thoracic surgery. We postulate that introducing dexmedetomidine to a combination of dezocine-based PCA drugs and sufentanil will increase female patients' global satisfaction degree.
METHODS:
One hundred fifty-two female patients with physical classification type I or II according to the American Society of Anesthesiologists undergoing thoracoscopic surgery were arbitrarily classified into two categories, either receiving sufentanil and dezocine-based PCIA (group C) or incorporating dexmedetomidine with sufentanil and dezocine-based PCIA (group D). The patients' global satisfaction degree, postoperative nausea and vomiting (PONV), PCA bolus, rescue analgesia requirements, drug-related adverse effects, rest and coughing visual analogue scale (VAS) ratings, and Ramsay sedation scores (RSS) were measured at 6, 12, 24, 36 and 48 h after surgery.
RESULTS:
Compared with the C group, the patient satisfaction degree was significantly higher; pain scores at rest and coughing were significantly different at 6, 12, 24, 36 and 48 h postoperatively; less rescue analgesia and PCA bolus were required; and a lower incidence of PONV was found in the D group. There were non-significant trends for the sedation scores and drug-related adverse effects in both groups.
CONCLUSIONS:
Dexmedetomidine combined with sufentanil and dezocine increased female patients' global satisfaction degree after thoracoscopic surgery. This effect could be linked to the improvement in postoperative analgesia and reduction in postoperative nausea and vomiting; the combined treatment did not increase drug-related adverse effects in female patients.
TRIAL REGISTRATION:
Chinese Clinical Trial Registry number, ChiCTR2000030429 . Registered on March 1, 2020.
AuthorsQiongzhen Li, Haixia Yao, Meiying Xu, Jingxiang Wu
JournalJournal of cardiothoracic surgery (J Cardiothorac Surg) Vol. 16 Issue 1 Pg. 102 (Apr 21 2021) ISSN: 1749-8090 [Electronic] England
PMID33882970 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Analgesics, Non-Narcotic
  • Analgesics, Opioid
  • Bridged Bicyclo Compounds, Heterocyclic
  • Tetrahydronaphthalenes
  • Dexmedetomidine
  • Sufentanil
  • dezocine
Topics
  • Adult
  • Analgesia (methods)
  • Analgesia, Patient-Controlled (adverse effects)
  • Analgesics, Non-Narcotic (therapeutic use)
  • Analgesics, Opioid (therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (administration & dosage)
  • Dexmedetomidine (administration & dosage)
  • Female
  • Humans
  • Middle Aged
  • Pain Management
  • Pain Measurement
  • Pain, Postoperative (etiology, surgery)
  • Patient Satisfaction
  • Postoperative Period
  • Sufentanil (administration & dosage)
  • Tetrahydronaphthalenes (administration & dosage)
  • Thoracoscopy
  • Time Factors
  • Treatment Outcome
  • Visual Analog Scale

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: